Gene therapy or immunotherapy: which approach is more likely to deliver a cure for HIV?
COVID-19 pandemic has speeded up the implementation of multi-month dispensing
New York studies look at COVID-19 outcomes and immune function among people with HIV
“If we don’t include women in trials, we are not protecting women” – dolutegravir in pregnant women living with HIV
Many people in African PrEP programmes stop and restart PrEP
Depo Provera may worsen tenofovir-related bone loss in young women
COVID-19 has had a major impact on PrEP, sexual behaviour and service provision
A second study finds introducing PrEP to Africa considerably reduces HIV infections in women
New assay finds low levels of intact proviral DNA in HIV elite controllers
